James T. Forbes

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, S. M. Steinberg, M Blichert-Toft et al. · PubMed · 1998 · 2.2K citations

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

Hirokazu Kurokawa, Anne E.G. Lenferink, Jean F. Simpson et al. · PubMed · 2000 · 367 citations

Tumor Biology, Breast Oncology, Endocrine-related Cancer +15

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.

Carlos L. Arteaga, Stephen D. Hurd, Angela R. Winnier et al. · Journal of Clinical Investigation · 1993 · 357 citations · Full text

Spleen Natural Killer, Breast Oncology, Immunology +17

Conditional Overexpression of Active Transforming Growth Factor β1 <b> <i>In vivo</i> </b> Accelerates Metastases of Transgenic Mammary Tumors

Rebecca S. Muraoka-Cook, Hirokazu Kurokawa, Yasuhiro Koh et al. · Cancer Research · 2004 · 159 citations · Full text

Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics

Michelle L. Reyzer, Robert L. Caldwell, Teresa C. Dugger et al. · Cancer Research · 2004 · 149 citations · Full text